Regnante Keith
SEC insider (Form 3/4/5 filer). CIK 0001682068. Chief Financial Officer at CITY THERAPEUTICS, INC. (CTY) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Feb 24, 2026. Located in CAMBRIDGE, MA.
Companies Regnante Keith has filed insider reports for
- CITY THERAPEUTICS, INC. (CTY): Officer, Chief Financial Officer
- Keros Therapeutics, Inc. (KROS): Officer, CHIEF FINANCIAL OFFICER
Regnante Keith
CIK: 0001682068
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (40.0%)
Position reduction
Option Exercises (M)1 (20.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Feb 24, 2026KROS
Keros Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
60K shares- - Feb 18, 2026KROS
Keros Therapeutics, Inc.
SaleDirect4.7K shares at avg. $16.35$77K - Feb 18, 2025KROS
Keros Therapeutics, Inc.
AwardDirect44K shares- - Jan 4, 2024KROS
Keros Therapeutics, Inc.
ExerciseDirect40K shares at avg. $16.00$640K - Jan 4, 2024KROS
Keros Therapeutics, Inc.
SaleDirect40K shares at avg. $45.29$1.8M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 24, 2026 |  KROS Keros Therapeutics, Inc. | Award Employee Stock Option (Right to Buy) | 60,000 | - | - | Direct |
| Feb 18, 2026 | KROS Keros Therapeutics, Inc. | Sale | 4,739 | $16.35 | $77,483 | Direct |
| Feb 18, 2025 | KROS Keros Therapeutics, Inc. | Award | 44,000 | - | - | Direct |
| Jan 4, 2024 | KROS Keros Therapeutics, Inc. | Exercise | 40,000 | $16.00 | $640,000 | Direct |
| Jan 4, 2024 | KROS Keros Therapeutics, Inc. | Sale | 40,000 | $45.29 | $1,811,600 | Direct |
1-5 of 5 transactions